| BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases B Lu, G Nagappan, X Guan, PJ Nathan, P Wren Nature Reviews Neuroscience 14 (6), 401-416, 2013 | 835 | 2013 |
| Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and … K Ahn, SE Smith, MB Liimatta, D Beidler, N Sadagopan, DT Dudley, ... Journal of Pharmacology and Experimental Therapeutics 338 (1), 114-124, 2011 | 252 | 2011 |
| Innervation of the foregut of the cockroach Leucophaea maderae and inhibition of spontaneous contractile activity by callatostatin neuropeptides H Duve, P Wren, A Thorpe Physiological Entomology 20 (1), 33-44, 1995 | 76 | 1995 |
| Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load V Calsolaro, PM Matthews, CK Donat, NR Livingston, GD Femminella, ... Molecular psychiatry 26 (10), 5848-5855, 2021 | 57 | 2021 |
| GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in … AR Rutter, A Poffe, P Cavallini, TG Davis, J Schneck, M Negri, E Vicentini, ... Journal of Pharmacology and Experimental Therapeutics 350 (1), 153-163, 2014 | 54 | 2014 |
| Serotonin–dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders MD Wood, PB Wren Progress in brain research 172, 213-230, 2008 | 44 | 2008 |
| Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals NR Livingston, V Calsolaro, R Hinz, J Nowell, S Raza, S Gentleman, ... Molecular psychiatry 27 (4), 2019-2029, 2022 | 32 | 2022 |
| The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl) methyl]-1, 3, 4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo [3 … TG Davis, JJ Peterson, JP Kou, EA Capper-Spudich, D Ball, AT Nials, ... Journal of Pharmacology and Experimental Therapeutics 330 (3), 922-931, 2009 | 27 | 2009 |
| Discovery of novel 1-cyclopentenyl-3-phenylureas as selective, brain penetrant, and orally bioavailable CXCR2 antagonists H Lu, T Yang, Z Xu, X Lin, Q Ding, Y Zhang, X Cai, K Dong, S Gong, ... Journal of Medicinal Chemistry 61 (6), 2518-2532, 2018 | 24 | 2018 |
| SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue C Scott, EM Soffin, M Hill, PJ Atkinson, CJ Langmead, PB Wren, S Faedo, ... European journal of pharmacology 536 (1-2), 54-61, 2006 | 18 | 2006 |
| Differential inhibition of LRRK2 in Parkinson's disease patient blood by a G2019S selective LRRK2 inhibitor JM Bright, HJ Carlisle, AMA Toda, M Murphy, TP Molitor, P Wren, ... Movement Disorders 36 (6), 1362-1371, 2021 | 16 | 2021 |
| 2-Aminopyrimidin-4 (1H)-one as the novel bioisostere of urea: discovery of novel and potent CXCR2 antagonists H Lu, T Yang, Z Xu, PB Wren, Y Zhang, X Cai, M Patel, K Dong, Q Zhang, ... Bioorganic & Medicinal Chemistry Letters 24 (23), 5493-5496, 2014 | 15 | 2014 |
| p38 MAP kinase activation does not stimulate serotonin transport in rat brain: Implications for sickness behaviour mechanisms F Andreetta, NM Barnes, PB Wren, L Carboni Life sciences 93 (1), 30-37, 2013 | 13 | 2013 |
| Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists R Palin, DR Barn, JK Clark, JE Cottney, PM Cowley, M Crockatt, L Evans, ... Bioorganic & medicinal chemistry letters 15 (3), 589-593, 2005 | 13 | 2005 |
| Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain K Ahn, SE Smith, MB Liimatta, D Beidler, N Sadagopan, DT Dudley, ... Journal of Pharmacology and Experimental Therapeutics, 2011 | 11 | 2011 |
| Longitudinal characterization of transcriptomic, functional, and morphological features in human iPSC-derived neurons and their application to investigate translational … G Robin, JC Evans, DN Hauser, P Wren, A Zembrzycki Frontiers in Aging Neuroscience 12, 576678, 2020 | 5 | 2020 |
| Mechanisms of vascular disease in dementia: what does industry want to know? PB Wren, D Hill, A Lockhart Clinical Science 131 (9), 799-802, 2017 | 5 | 2017 |
| Plasma lipid and liporotein biomarkers in LBC1936: Do they predict general cognitive ability and brain structure? SE Harris, SJ Ritchie, GDS Correia, B Jiménez, C Fawns-Ritchie, A Pattie, ... bioRxiv, 2020 | 1 | 2020 |
| The Identification of a Novel PDE4 Inhibitor, EPPA-1, with Improved Therapeutic Index using Pica Feeding in Rats as a Measure of Emetogenicity TG Davis, JJ Peterson, JP Kou, EA Capper-Spudich, D Ball, AT Nials, ... Journal of Pharmacology and Experimental Therapeutics, 2009 | 1 | 2009 |
| [P4–434]: PLASMA LIPID BIOMARKERS IN THE LOTHIAN BIRTH COHORT 1936: TOWARD ASSOCIATIONS WITH LIFE‐COURSE COGNITIVE FUNCTION SJ Ritchie, SE Harris, C Fawns‐Ritchie, JM Starr, DL Hill, P Wren, ... Alzheimer's & Dementia 13 (7S_Part_31), P1498-P1498, 2017 | | 2017 |
